Suresh Parvathy, Salem-Bekhit Mounir M, Veedu Hafsa Palathum, Alshehri Sultan, Nair Sreeja Chandrasekhar, Bukhari Sarah I, Viswanad Vidya, Taha Ehab I, Sahu Ram Kumar, Ghoneim Mohammed M, Elbagory Ibrahim
Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, India.
Kayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Nanomaterials (Basel). 2022 Apr 11;12(8):1299. doi: 10.3390/nano12081299.
Rheumatoid arthritis (RA) is a systemic, chronic autoimmune disease that causes disability due to progressive inflammation and destruction of the tissues around the joints. Methotrexate is mainly used to prevent the progression of joint destruction and reduce the deformity. The major challenge in treating RA with methotrexate is the systemic side effects that limit dose escalation. Hence, a novel formulation of a methotrexate-loaded nanoemulsion for subcutaneous administration was developed that aims to deliver methotrexate into the system via the lymph. The methotrexate-loaded nanoemulsion was prepared by using the aqueous-titration method. The prepared nanoemulsion was investigated for particle size, surface charge, surface morphology, entrapment efficiency, DSC (differential scanning colorimetry), drug release, hemocompatibility assay, and cytotoxicity, as well as anti-arthritic and stability studies. The vesicle size, zeta potential, PDI (polydispersity index), and entrapment efficiency of the optimized nanoemulsion were 87.89 ± 2.86 nm, 35.9 ± 0.73 mV, 0.27, and 87 ± 0.25%, respectively. The DSC study showed that the crystalline methotrexate was converted to an amorphous form and the drug was fully incorporated into the vesicles. After 72 h, the optimized nanoemulsion showed a drug release of 96.77 ± 0.63%, indicating a sustained-release dosage form. Cytocompatibility testing by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay on macrophage cell lines showed that the nanoemulsion was non-toxic. The formulation showed significant anti-arthritic activity compared to the marketed drug solution. In addition, the nanoemulsion containing methotrexate remained stable for three months when stored at a low temperature. Since the nanoemulsion containing methotrexate has excellent physicochemical properties and lowers systemic side effects by targeted delivery, it is a desirable technology for subcutaneous drug delivery.
类风湿性关节炎(RA)是一种全身性慢性自身免疫性疾病,由于关节周围组织的渐进性炎症和破坏而导致残疾。甲氨蝶呤主要用于预防关节破坏的进展并减少畸形。用甲氨蝶呤治疗RA的主要挑战是限制剂量增加的全身性副作用。因此,开发了一种用于皮下给药的载甲氨蝶呤纳米乳剂的新型制剂,其目的是通过淋巴将甲氨蝶呤输送到系统中。采用水相滴定法制备了载甲氨蝶呤纳米乳剂。对制备的纳米乳剂进行了粒径、表面电荷、表面形态、包封率、差示扫描量热法(DSC)、药物释放、血液相容性测定、细胞毒性以及抗关节炎和稳定性研究。优化后的纳米乳剂的囊泡大小、zeta电位、多分散指数(PDI)和包封率分别为87.89±2.86nm、35.9±0.73mV、0.27和87±0.25%。DSC研究表明,结晶甲氨蝶呤转变为无定形形式,药物完全掺入囊泡中。72小时后,优化后的纳米乳剂的药物释放率为96.77±0.63%,表明其为缓释剂型。通过MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基-2H-四氮唑溴盐)法对巨噬细胞系进行细胞相容性测试表明,该纳米乳剂无毒。与市售药物溶液相比,该制剂显示出显著的抗关节炎活性。此外,含甲氨蝶呤的纳米乳剂在低温下储存三个月仍保持稳定。由于含甲氨蝶呤的纳米乳剂具有优异的物理化学性质,并通过靶向递送降低全身性副作用,因此它是皮下给药的理想技术。